Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...
This is the first FDA approval of targeted therapy for pediatric patients <12 years of age with RET alterations. Selpercatinib was previously granted accelerated approval for thyroid cancer ...
The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET ...
Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...
Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions. The Food and Drug Administration (FDA) granted an accelerated approval to ...
A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. Background: RET gene alterations (mutations and fusions) leading to constitutive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results